1. Home
  2. GMAB vs LII Comparison

GMAB vs LII Comparison

Compare GMAB & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$27.19

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Logo Lennox International Inc.

LII

Lennox International Inc.

HOLD

Current Price

$499.80

Market Cap

15.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMAB
LII
Founded
1999
1895
Country
Denmark
United States
Employees
3029
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
16.9B
15.8B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
GMAB
LII
Price
$27.19
$499.80
Analyst Decision
Strong Buy
Hold
Analyst Count
8
13
Target Price
$39.81
$566.58
AVG Volume (30 Days)
1.6M
439.3K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
1.05%
EPS Growth
N/A
1.11
EPS
N/A
22.79
Revenue
N/A
$5,195,300,000.00
Revenue This Year
$17.85
$6.85
Revenue Next Year
$16.04
$5.76
P/E Ratio
$1.90
$21.62
Revenue Growth
N/A
N/A
52 Week Low
$18.89
$434.06
52 Week High
$35.43
$689.44

Technical Indicators

Market Signals
Indicator
GMAB
LII
Relative Strength Index (RSI) 44.70 53.56
Support Level $24.95 $481.66
Resistance Level $29.64 $498.78
Average True Range (ATR) 0.57 17.06
MACD 0.08 4.18
Stochastic Oscillator 23.26 66.61

Price Performance

Historical Comparison
GMAB
LII

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About LII Lennox International Inc.

Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.

Share on Social Networks: